Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | BCL9 | O00512 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.36 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.36 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.36 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1200910 | 0.88 | ELANE (0.43) | KMT2AKDM4EMEN1RECQLALOX15 | |
| SCHEMBL1199595 | 0.83 | PTGS2 (0.47) | KMT2AKDM4EMEN1LMNAPTGS2 | |
| Benzene SCHEMBL1200605 | 0.81 | PTGS2 (0.50) | KDM4ELMNAALOX15PTGS2TSHR | |
| SCHEMBL11425288 | 0.80 | KMT2A (0.50) | KMT2AKDM4EMEN1RECQLLMNA | |
| SCHEMBL1200603 | 0.79 | MAPK1 (0.47) | KMT2ALMNATSHR | |
| Naphthalene SCHEMBL1200947 | 0.79 | PTGS2 (0.44) | KMT2AKDM4ERECQLLMNAPTGS2 | |
| SCHEMBL9312497 | 0.79 | KMT2A (0.59) | KMT2AKDM4EMEN1RECQLLMNA | |
| SCHEMBL1200542 | 0.78 | CTDSP1 (0.46) | KMT2AKDM4EMEN1LMNAALOX15 | |
| SCHEMBL1201388 | 0.78 | ELANE (0.51) | LMNA | |
| SCHEMBL1901084 | 0.77 | PPARG (0.41) | KMT2AKDM4EMEN1LMNAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309753-B2 | Method for producing optically active cyanohydrin compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264005-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | CBR3, ACSL3, CCNL2 | KMT2A 1113/4885KDM4E 1728/4885MEN1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.